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Summary To evaluate the management of severe dysentery cases in in-patient facilities during an epidemic of Shigella
dysenteriae type 1 (Sd1), and to identify the factors associated with the risk of death, we conducted a
prospective cohort study in 10 Rwandese hospitals between September and December 1994. Data were
obtained from 849 cases admitted to hospitals with diarrhoea and visible blood in stools. The proportion
of patients with persistent bloody diarrhoea was 51.0% at treatment day 3 and 27.9% at treatment day 5.
At discharge, 79.9% had improved or were cured. The case fatality ratio was 13.2%, higher for patients
treated with nalidixic acid than for those treated with ciproﬂoxacin (12.2% vs. 2.2%, RR 5 5.80, 95%
CI 5 0.83–40.72). In a logistic regression model three risk factors were signiﬁcantly associated with an
increased risk of death during hospitalization: severe dehydration on admission (adjusted OR 5 2.79, 95%
CI 5 1.46–5.33), age over 50 (adjusted OR vs. 5–49 age group 5 3.22, 95% CI 5 1.70–6.11) and prescription
of nalidixic acid (adjusted OR vs. ciproﬂoxacin 5 8.66, 95% CI 5 1.08–69.67). Those results were consistent
with reported high levels of resistance of Sd1 to the commonest antibiotics, including nalidixic acid. Patients
belonging to groups with a higher risk of dying should be given special medical attention and supportive
care. In areas of high resistance to nalidixic acid, severe cases of dysentery should be treated with ﬂuoro-
quinolones in order to reduce the mortality associated with these epidemics.
keywords dysentery, Shigella dysenteriae type 1, antibiotic treatment, nalidixic acid, ﬂuoroquinolone,
Rwanda 
correspondence Dr Christophe Paquet, EPICENTRE, 8 rue Saint Sabin, 75011 Paris, France. E-mail:
cpaquet@epicentre.msf.org 
Introduction
For more than 10 years, epidemics of dysentery caused by
Shigella dysenteriae type 1 (Sd1) have been regularly affecting
Central African countries. Because of the increasing number
of cases reported each year, the high case fatality ratio (CFR)
associated with the disease, and the increasing cost of effec-
tive antibiotic treatment, dysentery has become a major pub-
lic health problem in these countries (WHO 1995).
The civil war that occurred in Rwanda in 1994, and the
population movements it induced, facilitated the transmission
of Sd1 (Paquet et al. 1995). A large outbreak of bloody diar-
rhoea started in July 1994 and spread all over the country.
The control of this outbreak has been further complicated by
the rapid progression of Sd1 resistance to the recommended
antibiotic treatment, nalidixic acid (Ries et al. 1994;
Ndihokubwayo et al. 1996).
In August 1994, Médecins Sans Frontières (MSF) started
assisting the newly appointed Ministry of Health in Rwanda
and, among other programmes, provided assistance to 10 dis-
trict hospitals covering 8 of the 9 préfectures of the country.
Between August and December 1994, dysentery was the ﬁrst
cause of admission and mortality in these hospitals. In order
to evaluate the management of severe dysentery cases in
Rwandan in-patient facilities, and to identify the factors
associated with the risk of death, we conducted a prospective
cohort study in the 10 district hospitals supported by MSF
between September and December 1994.
Methods
Study population
All patients admitted for dysentery in the 10 district hospitals
supported by MSF from September 15th to December 2ndTropical Medicine and International Health volume 4 no 6 pp 428–432 june 1999
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1994, were included in the study. Participating hospitals were
located in Kibuye, Gisenyi, Ruhengeri, Kigali, Gitarama,
Butare, Gikongoro and Cyangugu préfectures. Dysentery was
deﬁned as 3 or more liquid stools per day and the presence of
visible blood in stools, checked by medical personnel. Only
severe cases were treated in hospitals.
Data collection
A standardized data collection form was completed for each
patient admitted for dysentery, recording age, sex, history of
the disease, delay and self-medication before admission as
well as clinical presentation. Nutritional status, anaemia and
dehydration were assessed clinically by physicians in charge.
A follow-up clinical examination was performed daily be-
tween day 1 and day 5 and at discharge. There was no follow-
up after hospital discharge.
Outcome was recorded for each study patient on the day of
discharge. Outcome deﬁnitions were: ‘cured’, normal stools
or less than 3 liquid stools per day, and no visible blood in
stools; ‘improved’, 3 or more liquid stools per day, and no vis-
ible blood in stools; ‘treatment failure’: persistence of visible
blood in stools. Deaths of hospitalized dysentery patients
were also recorded.
Data analysis
Data were entered and analysed with Epi-Info 6.0. The rela-
tive risk (RR) with 95% conﬁdence interval was used to
measure the association between risk factors and the out-
come of the disease. A multivariate analysis (logistic regres-
sion) was performed using EGRET software (Epidemiological
Graphics, Estimation and Testing package, SERC). All vari-
ables included in the questionnaire, except those with more
than 10% missing values, were forced into regression models
(clinical signs, age group, delay on admission, self-medication
before admission and type of treatment). Adjusted odds
ratios (OR) were computed, and variables not associated with
the outcome and not identiﬁed as confounders were excluded
from the ﬁnal model.
Results
Sample description
A total of 849 cases of dysentery, admitted to MSF hospitals
between September 15th and December 2nd 1994, were
included in the study. The sex ratio (M/F) was 0.73 (339/463);
the median age on admission, 20. Three hundred and sixty-
one patients (42.5%) were less than 15 years old, 182 (21.4%)
were under 5, and 90 patients age 50 or older (10.6%)
(Table 1).
Past history and clinical presentation at admission
The median time lag between onset of symptoms and ad-
mission was 4 days, ranging from less than 24 h to 60 days.
Of 819 documented patients, 190 (23.2%) had taken some
kind of antibiotic treatment before admission (Table 1). Most
of the 160 patients with documented information had taken
nalidixic acid (68/160; 42.5%) and cotrimoxazol (50/160;
31.3%). None of the patients took ciproﬂoxacin before
admission.
Abdominal pain, tenesmus and fever (38.0 8C) were the
signs most commonly associated with bloody diarrhoea on
admission (Figure 1). Among admitted patients, 12.7%
(101/797) were recorded as severely dehydrated and 6.0%
(30/497) as severely malnourished.
Evolution and outcome
The median length of stay in hospital was 6 days, ranging
from less than 24 h to 41 days. The majority of the patients
were treated with nalidixic acid 4 g/day for 5 days (Table 1).
Nalidixic acid was the treatment recommended for dysentery
by the Rwandan Ministry of Health. However, two hospitals
(Gisenyi and Ruhengeri) had been allowed to use cipro-
ﬂoxacin because of their location close to the Zairian border,
where this drug was the ﬁrst-line treatment for the refugee
population. Thus 47 patients (5.5%) were treated with
ciproﬂoxacin.
At treatment day 3, 51.0% of the surviving patients
(413/810) had persisting bloody diarrhoea. This proportion
fell to 27.9% (219/785) at treatment day 5. At treatment
day 3, the proportion of patients with persisting bloody diar-
rhoea was higher among those receiving nalidixic acid than
among those receiving ciproﬂoxacin (56.9% vs. 30.4%,
RR 5 1.87, 95% CI 1.20–2.91). Similarly at treatment day 5,
bloody diarrhoea was more prevalent among patients treated
Table 1 Antibiotic treatment given on admission of 849 in-patients
dysentery cases, Rwanda 1994
Antibiotic treatment Number of cases (%)
Nalidixic acid 633 074.6
Ciproﬂoxacin 047 005.5
Chloramphenicol 037 004.4
Metronidazol 015 001.8
Ampicillin 014 001.6
Cotrimoxazol 013 001.5
Other 007 000.8
No antibiotic 029 003.4
Unknown 054 006.4
Total 849 100Tropical Medicine and International Health volume 4 no 6 pp 428–432 june 1999
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with nalidixic acid (31.6% vs. 17.4%, RR 5 1.82, 95% CI
0.96–3.45) (Figure 2).
Twenty-nine patients were lost to follow-up and outcome
was documented for the remaining 820 patients (96.6%). On
the day of discharge, 655 of 820 patients (79.9%) had im-
proved or were cured. This proportion was higher among
patients treated with ciproﬂoxacin (44/45 documented 5
97.8%) than among those who received nalidixic acid
(488/613 documented 5 79.6%) (RR 5 1.23, 95% CI
1.16–1.30). Fifty-seven (6.9%) treatment failures and 108
deaths (CFR 13.2%) were reported. The median duration of
stay in hospital for patients deceased was 4 days (range
0–35 days). Twenty-one of 108 deaths (20.0%) occurred
during the ﬁrst 48 h following admission.
Risk factors for death
Children under 5 (RR 5 1.5, 95% CI 1.0–2.3) and adults over
50 (RR 5 3.0, 95% CI 2.0–4.5) were at higher risk of dying
with reference to the 5–49 age group (Table 2). Seventy-nine
deaths (CFR 12.9%) were recorded among patients treated
with nalidixic acid and 1 (CFR 2.2%) among those who
received ciproﬂoxacin (RR 5 5.8, 95% CI 0.8–40.7) (Table 2).
The clinical symptoms recorded on admission signiﬁcantly
associated with an increased risk of death during hospital-
ization were severe dehydration, altered consciousness and
oedema of the legs (Table 2). The results of the ﬁnal logistic
regression model are shown in Table 3. Severe dehydration on
admission, oedema of the legs, age over 50 and age below 5
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Figure 1 Clinical signs on admission in 849
in-patient dysentery cases, Rwanda 1994.
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Figure 2 Proportion of in-patient dysentery
cases with persistent bloody diarrhoea from
admission to treatment day 5 according to
antibiotic treatment, Rwanda 1994.
d Ciproﬂoxacin; j Nalidixic acid; bars show
95% conﬁdence interval. At D0 n 5 633 for
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(vs. 5–49), and prescription of nalidixic acid (vs. cipro-
ﬂoxacin) were associated with an increased risk of death dur-
ing hospitalization.
Discussion
Our study was conducted during a large Sd1 outbreak in
Rwanda which lasted from July to December 1994. From
September on, we included almost all patients admitted with
bloody diarrhoea from 10 different hospitals throughout the
country. Since none of the hospitals was equipped to perform
bacteriological examinations, we used a clinical case deﬁ-
nition as inclusion criteria. However, various surveys, con-
ducted not only in Rwanda, but also in the refugee popula-
tions in the neighbouring countries of Zaire and Tanzania,
identiﬁed Sd1 as the causative agent of the dysentery out-
break that hit this part of Africa during the second half of
1994 (The Goma Epidemiology group 1995; Steering Com-
mittee of the Joint Evaluation of Emergency Assistance to
Rwanda 1996). We thus believe that our sample was represen-
tative of the severe Sd1 dysentery cases hospitalized in
Rwanda during the 1994 outbreak. However, this work was
performed in the context of an emergency rehabilitation pro-
gramme involving multiple centres, where successive ex-
patriate teams were in charge of collecting the data. As a
consequence, data collection may have suffered from lack of
homogeneity, and missing information might have biased our
results.
Overall, more than 13% of patients admitted for dysentery
in Rwanda died in hospital. Similar CFR were reported from
Bangladesh (Bennish & Wojtyniak 1991; Dutta et al. 1992)
and this conﬁrms the heavy human toll claimed by large Sd1
outbreaks in developing countries. In our cohort, as in
Bangladesh (Bennish & Wojtyniak 1991), the younger
patients as well as the elderly were at higher risk of dying.
The clinical presentation of severe dysentery cases in Rwanda
was similar to what had been reported from India (Mathan
& Mathan 1991). In our study severe dehydration was the
main clinical predictor of lethal outcome. This ﬁnding had
already been reported from Burundi (Huskins et al. 1994).
Our data also suggest that severe anaemia and oedema in the
legs on admission increased the risk of death in dysentery
patients. Although we did not have the means to diagnose
haemolytic uremic syndrome, this ﬁnding suggested that
some deaths could have been due to this complication.
Table 2 Factors associated with an increased risk of death during hospitalization of 849 in-patient dysentery cases (univariate analysis),
Rwanda 1994
Proportion of deaths  Proportion of deaths
Risk factors among exposed among nonexposed Relative risk 95% C I
Severe dehydration (clinical) 30/99 70/672 2.9  2.0–4.2
Altered consciousness 16/53 87/740 2.6  1.6–4.1
Oedema of the legs 18/67 84/732 2.3  1.5–3.7
Anuria 07/31 93/770 1.9 1.0–3.7
Severe anaemia (clinical) 06/28 87/719 1.8 0.9–3.7
Abdominal pain 89/685 09/85 1.2 0.6–2.3
Age group 0–4* 27/177 55/547 1.5  1.0–2.3
Age group > 50* 25/184 55/547 3.0 2.0–4.5
Self-medication § 23/182 81/608 1.0  0.6–1.5
Nalidixic acid † 79/613 01/45 5.8 0.8–40.7
Other antibiotics †,‡ 08/83 01/45 4.3 0.6–33.6
*: the nonexposed age group is 5–49; § history of self medication before admission (the nonexposed group did not take antibiotic); † the non-
exposed group received ciproﬂoxacin; ‡ ampicillin, chloramphenicol, cotrimoxazol, metronidazol.
Table 3 Factors associated with an increased risk of death during
hospitalization of 849 in-patient dysentery cases (logistic regression
model), Rwanda 1994
Risk factors Adjusted OR* 95% C I
Severe dehydration (clinical) 2.8 1.5–5.3
Severe anaemia (clinical) 2.6 0.8–8.5
Oedema of the legs 2.2 1.0–4.6
Age group 0–4§ 1.6 0.9–3.0
Age group _79 50§ 3.2 1.7–6.1
Nalidixic acid † 8.7 1.1–69.7
Other antibiotics†,‡ 5.8 0.6–53.5
* Odds ratios adjusted for: dehydration, age group, oedema of the
legs, antibiotic treatment, anaemia; § the reference age group is 5–49;
† the reference treatment group received ciproﬂoxacin; ‡ ampicillin,
chloramphenicol, cotrimoxazol, metronidazol.Tropical Medicine and International Health volume 4 no 6 pp 428–432 june 1999
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In Rwanda, patients treated with ciproﬂoxacin seemed to
have a much better cure rate than those treated with nalidixic
acid or other antibiotics. At treatment day 3, the proportion
of patients with persisting bloody diarrhoea was much lower
in the ciproﬂoxacin group, suggesting that this drug also
shortened the duration of the disease. However, only two
hospitals used ciproﬂoxacin and comparability of the differ-
ent groups of patients cannot be ensured. Differences in sup-
portive care or aetiologies of dysentery might have explained
these ﬁndings. The clinical condition of the patients admitted
might also have differed from one hospital to the other, but
multivariate analysis probably controlled for most of the
potential confounding effects of the clinical variables.
The progression of Sd1 resistance to the commonest anti-
biotics had already been reported from Burundi during the
1992 outbreak (Ries et al. 1994). A survey on in vitro Sd1
resistance was conducted at the time of the study period in
Rwanda. Thirty-nine (97.5%) of the 40 Sd1 strains isolated
were resistant to nalidixic acid, and 100% (40/40) to ampi-
cillin, chloramphenicol and cotrimoxazol (MSF & EPI-
CENTRE unpublished data). Should these results be
representative of the Sd1 strains that circulated in Rwanda in
1994, this would obviously explain the differences in out-
comes we observed among the antibiotic groups.
Our study, together with in vitro resistance surveys from
Rwanda and Burundi, suggests that in some parts of Africa
ﬂuoroquinolones such as ciproﬂoxacin might be the only
antibiotics still effective today against Sd1. In these areas,
introducing ciproﬂoxacin as ﬁrst-line treatment for serious
dysentery cases, under strict supervision, would probably
strongly reduce the high CFR of the disease. Fluoro-
quinolones are not recommended for children under 15
because of articular side-effects observed in growing animals,
but recent studies suggest that in humans this risk is actually
much lower than previously feared (Fontaine 1989; Schaad
1993). Moreover, the risk of complication due to treatment
must be balanced with the high CFR associated with Sd1
infection in the younger age groups.
The main factor that prevents recommending ﬂuoro-
quinolone as the treatment for serious dysentery cases in
African hospitals is current cost of the drug, given the poten-
tial number of patients to be treated in the course of a single
outbreak. Short-course ﬂuoroquinolone might represent a
less costly alternative to current 5 day treatment, but the efﬁ-
cacy of these therapeutic schemes against Sd1 remains to be
conﬁrmed (Bennish et al. 1992).